The ADVENT trial of Boston Scientific’s Farapulse pulsed field ablation (PFA) system met its primary and safety efficacy endpoints.
ADVENT is the first randomized trial to compare PFA to standard-of-care ablation with a radiofrequency or cryoablation ablation catheter in patients with drug-resistant paroxysmal atrial fibrillation. (Also see "JPM...